Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

Novotech

Southern Oncology Clinical Research Unit is a phase one cancer trials unit based in Adelaide, South Australia. It provides patients the opportunity to participate in ongoing cancer research while receiving clinical care from skilled health professionals. The unit conducts trials using various interventions including cytotoxic, targeted therapies, immunotherapy, and oncolytic viral therapies.

Southern Oncology Clinical Research Unit

Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

Science 37 Holdings, Inc.

Novotech Drug Development Consulting

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.   Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. 

For more information or to speak to an expert team member visit www.Novotech-CRO.com

Sequoia Capital

Happy Lunar New Year! Best wishes for a successful and prosperous Year of the Dragon. May this year bring continued advancements and achievements in the field of Clinical Trials. Here's to another year of meaningful contributions to healthcare and research excellence! 

#LunarNewYear #ClinicalTrials #YearOfTheDragon

On World Cancer Day, Novotech, affirms its commitment to working with biotechs worldwide to advance breakthroughs in cancer treatment.   

#CloseTheCareGap #WorldCancerDay #ClinicalTrials

The #Novotech team had an amazing time engaging with the clinical research community at last week’s 17th Annual ISCR Conference in India!

If you missed the chance to visit us during the conference, connect with us here- https://lnkd.in/gk8sj5HE

Bableen Sethi, Kanhaiya Choudhary 

#ISCRConference #ClinicalResearch #Innovation

In a recent visit, Dr. John Moller, CEO of Novotech, and Dr. Yooni Kim, Global Vice President and Head of Clinical Services, had the opportunity to engage with Lee Seung Kyou, Vice Chairman of Korea Bio. The organization is dedicated to strengthening connections within the bioindustry, reinvigorating related companies by actively promoting technological development and industrialization to foster the growth of the national economy. According to Korea Bio, “As of 2022, South Korea had a total of 1,089 biotech companies”. Novotech looks forward to sustaining its longstanding relationship in South Korea and continuing its support for the biotech industry.

#clinicalresearch #KoreaBio

In honor of Black History Month, let’s celebrate the pioneering achievements of African American scientists and doctors who’ve made lasting impacts on healthcare and scientific advancements.

#blackhistorymonth #clinicaltrials #clinicalresearch

In this enlightening interview, Passant Zaki, the Associate Director of Clinical Operations at Novotech, shared her inspiring professional journey through progressively advancing roles in clinical trial management. Her compelling career path underscored a harmonious blend of hands-on experience, education, and an unwavering dedication to continuous learning.

Also Passant perspectives offer a glimpse into the challenges and vast potential impact of advancing new therapies through dedicated leadership in healthcare research.
Watch it now!

#ClinicalResearchAssociate #Clinicaltials #CRA #closethecaregap

Stop by booth #6 at the India Society for Clinical Research (ISCR) 17th Annual Conference taking place today and tomorrow in Hyderabad, India and connect with the Novotech team! Discover how our expertise can elevate your clinical trial plans in 2024 and beyond.

Bableen Sethi, Kanhaiya Choudhary

#ISCR2024 #ClinicalTrials #CRO

Novotech’s CEO, Dr. John Moller, recently met with the newly appointed Australian Ambassador to the Republic of Korea, Mr. Jeff Robinson. Accompanying him were key members from the Novotech team, Dr. Yooni Kim, Global Vice President, Head of Clinical Services and Lilian K., Senior Director Business Development. 

A fruitful discussion ensued with Ambassador Robinson recognizing Novotech as a leading global CRO with headquarters in Australia. Both parties look forward to creating a synergistic relationship in the Republic of Korea.

#AusTrade #ClinicalTrials #CRO

Novotech is thrilled to announce our sponsorship for the upcoming OCT West Coast conference, happening on February 6-7 in Burlingame, California.

Join us at 𝐁𝐨𝐨𝐭𝐡 𝟕𝟔, where our experts will be available to discuss customized solutions that can fast-track the advancement of your #clinicaltrials.

Click here to get in touch with our experts- https://lnkd.in/gFqhvEAN

Diana Filipescu, Aditya Kotta, Rod Bugawan, Alex Ireland
#OCTWestCoast #CRO #DrugDevelopment

Metric
Company Name	Novotech	Southern Oncology Clinical Research Unit	Science 37 Holdings, Inc.
Symbol			SNCE
MSH ID	COM:NOVOTECH-CRO	AU:ORG:SOCRU	COM:SCIENCE37
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology Research	Medical Research	Medical - Healthcare Information Services
Country	AU	AU	US
Stage
Employee Count	1.99K		460
Website	novotech-cro.com	socru.org.au	science37.com
LinkedIn	novotech
Founders

Metric
Market Cap			34.66M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			70.15M
Revenue (LTM)
Revenue (NTM)
Gross Profit			15.87M
EBITDA			-139.41M
Operating Income			-105.33M
Net Income			-50.99M
EPS			-0.44
Diluted EPS			-0.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.30
Operating Profit Margin			-0.49
EBITDA Margin			-1.99
Net Profit Margin			-2.05
Return on Equity			-1.71
Return on Assets			-1.63
Return on Capital Employed			-0.51

COM:NOVOTECH-CRO

Novotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-5.44
P/B Ratio			12.99
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			0.58
EV Multiple			6.57

Metric
Days Sales Outstanding			76.26
Days Payables Outstanding			57.46
Days Inventory Outstanding			53.22
Operating Cycle			129.48
Cash Conversion Cycle			72.02
Asset Turnover			0.80

Metric
Operating Cash Flow			-75.44M
Free Cash Flow			-107.32M
Cash Flow to Debt			-82.94
Operating Cash Flow/Sales			-0.80
Free Cash Flow Yield			-2.15

Metric
Cash & Equivalents			108.09M
Accounts Receivable			-821
Inventory
Goodwill
Debt to Capitalization			0.01
Debt to Assets			0.01
Current Ratio			4.17
Quick Ratio			3.81

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.29
R&D to Revenue
SG&A to Revenue			0.00